Response of progressive fibromatosis to therapy with liposomal doxorubicin

Onkologie

Volumn 27, Issue 6, 2004, Pages 552-556

  Wehl, G ^a   Rossler, J ^a   Otten, J E ^a   Boehm, N ^a   Uhl, M ^a   Kontny, U ^a   Niemeyer, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cardiotoxicity; Childhood; Doxorubicin, pegylated liposomal; Fibromatosis

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ABDOMINAL FIBROMATOSIS; ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; CHEMOTHERAPY INDUCED EMESIS; ECHOCARDIOGRAPHY; FEMALE; FIBROMATOSIS; HUMAN; MALE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; DISEASE PROGRESSION; DOXORUBICIN; FACIAL NEOPLASMS; FEMALE; FIBROMATOSIS, ABDOMINAL; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; MOUTH NEOPLASMS; NOSE NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 10844229237     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081337     Document Type: Article

References (33)

1. Coffin CM, Dehner LP: Fibroblastic-myofibroblastic tumors in children and adolescents: A clinicopathologic study of 108 examples in 103 patients. Pediatr Pathol 1991;4:569-588.
2. Allen PW: The fibromatoses. A clincopathological classification based on 140 cases. Part 1. Am J Surg Pathol 1977;1:255-270.
3. Allen PW: The fibromatoses. A clincopathological classification based on 140 cases. Part 2. Am J Surg Pathol 1977;1:305-321.
4. Wiswell TE, Davis J, Cunningham BE, Solenberger R, Thomas PJ: Infantile myofibromatosis: The most common fibrous tumor of infancy. J Pediatr Surg 1988;23:315-318.
5. Chung EB, Enzinger FM: Infantile myofibromatosis. Cancer 1981;48:1807-1818.
6. Wiswell TE, Sakas EL, Stephanson SR, Lesica JJ, Reddoch SR: Infantile myofibromatosis. Pediatrics 1985;76:981-984.
7. Schmidt, D: Fibrous tumors and tumor-like lesions of childhood: Diagnosis, differential diagnosis, and prognosis. Curr Top Pathol 1995;89:175-191.
8. Gardner EJ, Richards RC: Multiple cutaneous and subcutaneous lesions occuring simultaneously with hereditary polyposis and osteomatosis. Am J Hum Genet 1953;5:139-147.
9. Ayala AG, Ro JY, Goepfert H, Cangir A, Khorsand J, Flake G: Desmoid fibromatosis. A clinicopathological study of 25 children. Semin Diag Pathol 1986;3:138-150.
10. Seiter K, Kemeny N: Successful treatment of a desmoid tumor with doxorubicin. Cancer 1993;71:2242-2244.
11. Baliski CR, Temple WJ, Arthur K, Schachar NS. Desmoid tumors. A novel approach for local control. J Surg Oncol 2002;80:96-99.
12. Von Hoff DD, Layard MW, Basa P, Davis HL Jr., Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
13. Theodoulou M, Hudis C: Cardiac profiles of liposomal anthracyclines. Cancer 2004;100:2052-2063.
14. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711-716.
15. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, Henderson R, Berry G, Gabizon A: Pegylated liposomal doxorubicin [doxil]: Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-1033.
16. Gabizon AA, Lyass O: Cardiac safety of pegylated liposomal doxorubicin demonstrated by endomyocardial biopsy in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003;22:763.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom T, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92:205-216.
18. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS: The pharmacological treatment of aggressive fibromatosis: A systematic review. Ann Oncol 2003; 14:181-190.
19. Okuno SH, Edmonson JH: Combination chemotherapy for desmoid tumors. Cancer 2003;15:1134-1135.
20. Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, Ferguson WS, Grier HE: Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid fibromatosis in children. J Clin Oncol 1998;16:3021-3027.
21. Williams W, Craver RD, Correa H, Velez M, Gardner RV: Use of 2-chlorodeoxyadenosine to treat infantile myofibromatosis. J Pediatr Hematol Oncol 2002;24:59-63.
22. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ: Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983;52:2201-2204.
23. Waddell WR, Kisch WM: Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991;161:416-421.
24. Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L: Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.
25. Working PK, Dayan AD: Pharmacological-toxicological expert report. CAELYX (stealth liposomal doxorubicin HCl). Hum Exp Toxicol 1996;15:751-785.
26. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 1997;15:3185-3191.
27. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP: Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999;10:1113-1116.
28. Dvorak J, Zoul Z, Melichar B, Jandik P, Mergancova J, Hrncirova I, Urminska H, Petera J: Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: A case report. Onkologie 2001;24:166-168.
29. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian cancer: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
30. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP: Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: A Pediatric Oncology Group Study. Clin Cancer Res 2002;8:413-418.
31. Joerger M, Oehlschlegel C, Cerny T, Gillessen S: Postradiation high-grade myofibroblastic sarcoma of the prostate - a rare entity of prostatic tumors - responding to liposomal Doxorubicin. Onkologie 2002;25:558-561.
32. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-2879.
33. Steinherz LJ, Steinherz PG, Tan C: Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: A series of 15 patients. Med Pediatr Oncol 1995;24:352-361.